Hearing loss prevention pill put to the test — but study never started
NCT ID NCT02779192
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to test whether an oral drug called SPI-1005 (ebselen) could prevent temporary hearing loss caused by loud noise. Researchers planned to enroll adults aged 18-50 with a history of noise exposure and give them the drug or a placebo for 7 days, then measure hearing changes after a controlled sound challenge. However, the trial was withdrawn before any participants were enrolled, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- SPI-1005 (ebselen)
- What this could lead to
- If it works, this could point toward a pill that protects against hearing loss from loud noise.
- What could go wrong
- The study was withdrawn before enrolling anyone, so no results exist. It is unclear if the drug is effective or safe for this use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 50 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult male or female patients, 18-50 years of age * History of either recreational and/or occupational exposure to noise * Voluntarily consent to participate in the study * Females of childbearing potential should be using and committed to continue using one of the following acceptable birth control methods: Sexual abstinence (inactivity) for 14 days prior to screening through study completion; or intra-uterine device in place for at least 3 months prior to study through study completion; or barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening through study completion; or stable hormonal contraceptive for at least 3 months prior to study through study completion; or surgical sterilization (vasectomy) of partner at least 6 months prior to study. * Females of non-childbearing potential should be surgically sterile (bilateral tubal ligation with surgery at least 6 months prior to study, hysterectomy, or bilateral oophorectomy at least 2 months prior to study) or be at least 3 years since last menses. Exclusion Criteria: * Current use or within 60 days prior to study of excluded ototoxic medications * History of autoimmune inner ear disease * History of middle ear or inner ear surgery * Current conductive hearing loss or middle ear effusion * Significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, or psychiatric disease * History of hypersensitivity or idiosyncratic reaction to compounds related to ebselen * Current use or within 30 days prior to study of drugs or substances known to be strong inhibitors or inducers of cytochrome P450 enzymes * Participation in another investigational drug or device study within 90 days prior to study enrollment * Female patients who are pregnant or breastfeeding
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Noise-induced hearing loss are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MUSC
Charleston, South Carolina, 29425, United States
-
Sound Pharmaceuticals, Inc.
Seattle, Washington, 98103, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66103, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of Texas Southwestern
Dallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 3-Minute video beat a pamphlet at saving hearing?
- Chilling the inner ear: a cool new way to shield hearing?
- Hearing loss injection study pulled before it began
- Can talking circles save native american hearing?
- Classroom lessons aim to stop hearing loss before it starts
- Can stem cells restore hearing? early trial aims to find out